Tumor Biology

, Volume 36, Issue 4, pp 2403–2407 | Cite as

Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer

Research Article

Abstract

Long non-coding RNAs (lncRNAs) have been proved to serve as a critical role in cancer development and progression. However, little is known about the pathological role of lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in pancreatic cancer patients. The aims of this study are to measure the expression of lncRNA MALAT1 in pancreatic cancer patients and to explore the clinical significance of the lncRNA MALAT1. Using qRT-PCR, the expression of lncRNA MALAT1 was measured in 126 pancreatic cancer tissues and 15 adjacent non-cancerous tissues. In the present study, our results indicated that lncRNA MALAT1 was highly expressed in pancreatic cancer compared with adjacent non-cancerous tissues (P < 0.001), and positively correlated with clinical stage (early stages vs. advanced stages, P < 0.001), tumor size (<2 vs. ≥2 cm, P = 0.004), lymph node metastasis (negative vs. positive, P < 0.001), and distant metastasis (absent vs. present, P = 0.001) in pancreatic cancer patients. Furthermore, we also found that lncRNA MALAT1 overexpression was an unfavorable prognostic factor in pancreatic cancer patients (P < 0.001), regardless of clinical stage, tumor size, lymph node metastasis, and distant metastasis. Finally, increased lncRNA MALAT1 expression was an independent poor prognostic factor for pancreatic patients through multivariate analysis (P = 0.018). In conclusion, overexpression of lncRNA MALAT1 serves as an unfavorable prognostic biomarker in pancreatic cancer patients.

Keywords

lncRNA MALAT1 Pancreatic cancer Prognosis 

Notes

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64(1):9–29. doi: 10.3322/caac.21208.Google Scholar
  2. 2.
    Guo X, Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas. 2005;31(1):13–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Chen Y, Hao J, Ma W, Tang Y, Gao C, Hao X. Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China. J Gastrointest Surg: Off J Soc Surg Aliment Tract. 2011;15(6):1026–34. doi: 10.1007/s11605-011-1493-y.CrossRefGoogle Scholar
  4. 4.
    Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163–72. doi: 10.1038/nrclinonc.2009.236.CrossRefPubMedGoogle Scholar
  5. 5.
    Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990–2010. World J Gastroenterol: WJG. 2011;17(7):867–97. doi: 10.3748/wjg.v17.i7.867.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014;1839(11):1097–109. doi: 10.1016/j.bbagrm.2014.08.012.CrossRefPubMedGoogle Scholar
  7. 7.
    Mattick JS. The genetic signatures of noncoding RNAs. PLoS Genet. 2009;5(4):e1000459. doi: 10.1371/journal.pgen.1000459.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Tahira AC, Kubrusly MS, Faria MF, Dazzani B, Fonseca RS, Maracaja-Coutinho V, et al. Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer. 2011;10:141. doi: 10.1186/1476-4598-10-141.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sun YW, Chen YF, Li J, Huo YM, Liu DJ, Hua R, et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1alpha in pancreatic ductal adenocarcinoma. Br J Cancer. 2014. doi: 10.1038/bjc.2014.520.Google Scholar
  10. 10.
    Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, et al. H19 promotes pancreatic cancer metastasis by derepressing let-7′s suppression on its target HMGA2-mediated EMT. Tumour Biol: J Int Soc Oncodev Biol Med. 2014;35(9):9163–9. doi: 10.1007/s13277-014-2185-5.CrossRefGoogle Scholar
  11. 11.
    Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616–25. doi: 10.1038/onc.2012.193.CrossRefPubMedGoogle Scholar
  12. 12.
    Gutschner T, Hammerle M, Diederichs S. MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med (Berlin, Germany). 2013;91(7):791–801. doi: 10.1007/s00109-013-1028-y.CrossRefGoogle Scholar
  13. 13.
    Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–41. doi: 10.1038/sj.onc.1206928.CrossRefPubMedGoogle Scholar
  14. 14.
    Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer. 2011;6(12):1984–92. doi: 10.1097/JTO.0b013e3182307eac.CrossRefGoogle Scholar
  15. 15.
    Han Y, Liu Y, Nie L, Gui Y, Cai Z. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder. Urology. 2013;81(1):209 e201–207. doi: 10.1016/j.urology.2012.08.044.CrossRefGoogle Scholar
  16. 16.
    Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol BioSyst. 2012;8(9):2289–94. doi: 10.1039/c2mb25070e.CrossRefPubMedGoogle Scholar
  17. 17.
    Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007;26(6):851–8. doi: 10.1038/sj.onc.1209846.CrossRefPubMedGoogle Scholar
  18. 18.
    Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology (Baltim, Md). 2006;44(4):1012–24. doi: 10.1002/hep.21328.CrossRefGoogle Scholar
  19. 19.
    Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol: Off J U S Can Acad Pathol Inc. 2007;20(10):1085–94. doi: 10.1038/modpathol.3800937.CrossRefGoogle Scholar
  20. 20.
    Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014;32(6):2485–92. doi: 10.3892/or.2014.3518.PubMedGoogle Scholar
  21. 21.
    Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14(8):2334–40. doi: 10.1158/1078-0432.ccr-07-4667.CrossRefGoogle Scholar
  22. 22.
    Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–69. doi: 10.1534/genetics.112.146704.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Maruyama R, Suzuki H. Long noncoding RNA involvement in cancer. BMB Rep. 2012;45(11):604–11.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Liu JH, Chen G, Dang YW, Li CJ, Luo DZ. Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues. Asian Pac J Cancer Prev: APJCP. 2014;15(7):2971–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol (Northwood, London, England). 2012;29(3):1810–6. doi: 10.1007/s12032-011-0004-z.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of SurgeryThe Sixth People’s Hospital Affiliated to Shanghai Jiao Tong UniversityShanghaiChina
  2. 2.Department of General SurgeryThe Fifth Hospital of WuhanWuhanChina
  3. 3.Department of Hepatobiliary SurgeryLiaoning Cancer Hospital & Institute, Dalian Medical University Clinical Oncology CollegeDalianChina

Personalised recommendations